NASDAQ:ENDP Endo International (ENDP) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0090▼$0.0150-Day Range$0.28▼$0.7552-Week Range$0.28▼$7.07Volume75,712 shsAverage Volume28.19 million shsMarket Capitalization$2.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Endo International MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainability-2.62Upright™ Environmental ScoreNews Sentiment0.01Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth-83.33%From $0.78 to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.95 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Endo International. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ENDP. Previous Next 0.0 Dividend Strength Dividend YieldEndo International does not currently pay a dividend.Dividend GrowthEndo International does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEndo International has received a 40.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Frovatriptan succinate", "Other cancer medication", "Isosorbide dinitrate", "Oxycodone", "Cyanocobalamin", and "Paracetamol" products. See details.Environmental SustainabilityThe Environmental Impact score for Endo International is -2.62. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Endo International this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Endo International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Endo International is held by insiders.Percentage Held by Institutions80.39% of the stock of Endo International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Endo International are expected to decrease by -83.33% in the coming year, from $0.78 to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Endo International (NASDAQ:ENDP) StockEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.Read More ENDP Stock News HeadlinesSeptember 21, 2023 | markets.businessinsider.comEndo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual MeetingSeptember 18, 2023 | prnewswire.comPreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD ApplicationSeptember 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 4, 2023 | marketwatch.comHelp My Career: The true call of duty? How women veterans can get the higher-paying civilian jobs they deserveAugust 23, 2023 | mirror.co.ukLiverpool complete Wataru Endo transfer after double rejection forces surprise moveAugust 20, 2023 | benzinga.comFrom Trump's Indictments To DeSantis' Poll Drop And Musk's GOP Endorsement: Top Political Stories This WeekAugust 4, 2023 | prnewswire.comWomen's Health Global Marketplace 2023-2030: Endometriosis Applications Poised for Remarkable Expansion with Relugoliz and Linzagolix Set to Lead the WayAugust 1, 2023 | finance.yahoo.comBankrupt Endo says US government objections imperil $600 mln in opioid settlementsSeptember 22, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>July 30, 2023 | bitcoinist.comBitcoin Bug Bounty Initiative Endorsed By Human Rights Foundation To Aid Activists GloballyJuly 22, 2023 | benzinga.comJFK's Grandson Says RFK Jr.'s Presidential Bid Is For 'Personal Gain And Fame:' Endorses BidenJuly 15, 2023 | benzinga.comEndo Presents New Data at the American Podiatric Medical Association Annual MeetingJuly 12, 2023 | bitcoinist.comFantom Foundation Addresses Community On Multichain Exploit, Endorses Two Bridging SolutionsJuly 11, 2023 | gurufocus.comLilly Endowment Inc. Reduces Stake in Eli Lilly and Co.July 11, 2023 | gurufocus.comLilly Endowment Inc Reduces Stake in Eli Lilly and CoJuly 8, 2023 | benzinga.comTrump Says DeSantis Was A 'Lousy Candidate' With 'No Personality' For Governor Until His EndorsementJuly 4, 2023 | wsj.comNew FTC Guidelines Could Prompt Marketers, Influencers to Revisit Endorsement PracticesJune 26, 2023 | benzinga.comEndo Announces First Patient Enrolled in Registry of Dupuytren's ContractureMay 15, 2023 | marketwatch.comCOP Syringes Market in 2023: Insights and Strategies | 2031April 20, 2023 | finance.yahoo.comEndo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label ProgramApril 17, 2023 | thestreet.comEndo International (ENDP) Is Today's Water-Logged And Getting Wetter StockApril 6, 2023 | bizjournals.comEndo bankruptcy auction moving ahead with bids to start at $6BMarch 31, 2023 | prnewswire.comEndoTech.io Announces Technology Integration with OKX Exchange, Enabling User Access to Volatility with AI AlgorithmsMarch 30, 2023 | benzinga.comPope-Endorsed Candidate Running Against Corporate Cannabis And Monoculture In Argentina's Pres ElectionsMarch 28, 2023 | benzinga.comMerck Releases Keytruda Data In Frontline Endometrial Cancer PatientsMarch 27, 2023 | benzinga.comElon Musk-Endorsed Baby Doge Coin Leaps 7%, Leaving Shiba Inu, Dogecoin In The DustMarch 23, 2023 | financialpost.comCoveo AI Search and Recommendations Platform for SAP® Commerce Cloud Now an SAP® Endorsed AppSee More Headlines Receive ENDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter. Email Address ENDP Company Calendar Last Earnings11/04/2021Today9/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ENDP CUSIP29264F20 CIK1593034 Webwww.endo.com Phone(531) 268-2000Fax800-329-3636Employees3,103Year Founded1997Profitability EPS (Most Recent Fiscal Year)($11.07) Trailing P/E RatioN/A Forward P/E Ratio0.01 P/E GrowthN/ANet Income$-613,240,000.00 Net Margins-93.31% Pretax Margin-91.14% Return on Equity-34.25% Return on Assets6.72% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.62 Sales & Book Value Annual Sales$2.99 billion Price / Sales0.00 Cash Flow$0.17 per share Price / Cash Flow0.06 Book Value($13.60) per share Price / Book0.00Miscellaneous Outstanding Shares235,143,000Free Float232,321,000Market Cap$2.35 million OptionableOptionable Beta1.15 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Blaise A. Coleman (Age 48)Pres, CEO & Director Comp: $20.93MMr. Mark T. Bradley (Age 52)Exec. VP & CFO Comp: $6.27MMr. Matthew Joseph Maletta (Age 50)Exec. VP, Chief Legal Officer & Company Sec. Comp: $7.02MMr. Patrick A. Barry (Age 54)Exec. VP & Pres of Global Commercial Operations Comp: $6.15MFrank B. RacitiVP, Controller & Chief Accounting OfficerMs. Cheryl StouchSr. VP of Information Technology & Chief Information OfficerMs. Laure E. ParkSr. VP of Investor Relations & Corp. AffairsMs. Susan WilliamsonSr. VP & Chief Compliance OfficerMs. Tracy BassoChief HR OfficerMr. James PappHead of Endo Ventures Limited & Sr. VP of Global Supply ChainMore ExecutivesKey CompetitorsAvalo TherapeuticsNASDAQ:AVTXFirst Wave BioPharmaNASDAQ:FWBIAllarity TherapeuticsNASDAQ:ALLRNeptune Wellness SolutionsNASDAQ:NEPTNeuBase TherapeuticsNASDAQ:NBSEView All Competitors ENDP Stock - Frequently Asked Questions How were Endo International's earnings last quarter? Endo International plc (NASDAQ:ENDP) announced its earnings results on Thursday, November, 4th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.34. The firm had revenue of $772.03 million for the quarter, compared to analyst estimates of $667.94 million. Endo International had a negative trailing twelve-month return on equity of 34.25% and a negative net margin of 93.31%. The business's revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 EPS. What is Paul Campanelli's approval rating as Endo International's CEO? 25 employees have rated Endo International Chief Executive Officer Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among the company's employees. What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA). What is Endo International's stock symbol? Endo International trades on the NASDAQ under the ticker symbol "ENDP." What is Endo International's stock price today? One share of ENDP stock can currently be purchased for approximately $0.01. How much money does Endo International make? Endo International (NASDAQ:ENDP) has a market capitalization of $2.35 million and generates $2.99 billion in revenue each year. The company earns $-613,240,000.00 in net income (profit) each year or ($11.07) on an earnings per share basis. How many employees does Endo International have? The company employs 3,103 workers across the globe. How can I contact Endo International? Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The official website for the company is www.endo.com. The company can be reached via phone at (531) 268-2000, via email at relations.investor@endo.com, or via fax at 800-329-3636. This page (NASDAQ:ENDP) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endo International plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.